Chugai Seiyaku Kabushiki Kaisha

Hoffmann-La Roche Inc.

Yasunori Kohchi

Nobuo Shimma

Hitoshi Iikura

Kazuo Hattori

Yoshiaki Isshiki

Nobuhiro Oikawa

Hideo Ishitsuka

Hitomi Suda

Masanori Miwa

Tohru Ishikawa

Yasuaki Matsubara

Satoshi Aida

Takeshi Murata

Eisaku Mizuguchi

Masami Kohchi

Kosuke Aso

Shinji Tsujii

Susumu Komiyama

Fumio Watanabe

Hiroshi Koyano

Kimitaka Nakama

Naohito Inagaki

An object of the present invention is to provide a compound that is useful as an orally available anti-HCV agent. The present invention relates to a compound represented by formula (1) or a pharmaceutically acceptable salt thereof. This compound has an anti-HCV activity and is useful as a medicine.

Orally available viridiofungin derivative possessing anti-HCV activity

An objective of the present invention is to provide compounds that exhibit strong MEK-inhibiting activity and are stable in vivo and soluble in water, which can be used as preventive or therapeutic agents for proliferative diseases. The compounds of the present invention and pharmaceutically acceptable salts thereof are represented by the following formula (1): [where R, R, R, R, and X are the same as defined in the present patent application].

5-substituted-2-phenylamino benzamides as MEK inhibitors

A compound of the present invention, or a pharmaceutically acceptable salt thereof is indicated by formula (1) below: wherein, R, R, R, R, R, R, Q, R, and Rhave the same meanings as R, R, R, R, R, R, Q, R, and Rin the specification.

4-phenylamino-benzaldoxime derivatives and uses thereof as mitogen-activated protein kinase kinase (MEK) inhibitors

The invention provides a process for production of 2,3,4-trifluoro-5-(iodo or bromo)benzoic acid, the process comprising a halogenation step in which direct iodination or bromination of 2,3,4-trifluorobenzoic acid is performed with an iodinating agent or brominating agent in a reaction solvent in the presence of an oxidizing agent. According to the invention, there is provided a process for convenient production of 2,3,4-trifluoro-5-(iodo or bromo)benzoic acid in high yield and high purity in a highly regioselective manner.

Process for production of 2,3,4-trifluoro-5-(iodo or bromo)-benzoic acid

5-Substituted-2-phenylamino benzamides as MEK inhibitors

Novel 5&prime;-deoxy-cytidine derivatives represented by the general formula (I)

5&prime;-deoxy-cytidine derivative administration to treat solid tumors

Novel 5'-deoxy-cytidine derivatives represented by the general formula (I) ##STR1## wherein R.sup.1 is a hydrogen atom or a group easily hydrolyzable under physiological conditions; R.sup.2 is a hydrogen atom, or --CO--OR.sup.4 group [wherein R.sup.4 is a saturated or unsaturated, straight or branched hydrocarbon group consisting of one to fifteen carbon atoms, or a group of the formula --(CH.sub.2).sub.n --Y (in which Y is cyclohexyl or phenyl; n is an integer from 0 to 4)]; R.sup.3 is a hydrogen atom, bromo, iodo, cyano, a C.sub.1-4 alkyl group [which may be substituted with halogen atom(s)], a vinyl or ethynyl group [which may be substituted with halogen atom(s), C.sub.1-4 alkyl, cycloalkyl, aralkyl, or aromatic ring which may have one or more hetero atom(s)], or an aralkyl group which may be substituted for use in medical therapy, especially tumor therapy.

5'-deoxy-cytidine derivatives

Compounds of the formula (I) ##STR1## wherein R.sup.1 is each independently hydrogen or a group easily hydrolyzable under physiological conditions;

5'deoxycytidine derivatives

Growing community of inventors

Kanagawa, Japan

Yasunori Kohchi